share_log

HC Wainwright & Co. Reiterates Buy on Dyne Therapeutics, Maintains $36 Price Target

Benzinga ·  May 3 15:46

HC Wainwright & Co. analyst Andrew Fein reiterates Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $36 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment